IMA
ImageneBio IncHealthcare·Biotechnology
$5.88
$66M market cap
Revenue
$0.0M
Free Cash Flow
$-22.0M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably nonâdepleting antiâOX40 monoclonal antibody IMGâ007 in Phase 2b for atopic dermatitis
2-Year Price History
$5.56-73.8%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -12.1 | -12.1 | -10.6 | -14.8 | -14.8 | -0.0 | 117.2 | 8.2 | 11.2 | -118.0% | -- | -- |
| Act | 2025-Q4 | 0.0 | -7.9 | -8.5 | -6.9 | -7.2 | -7.2 | -0.0 | 75.8 | 10.0 | 11.2 | -61.8% | -- | -- |
Valuation & Metrics
Market Stats
Price$5.88
Market Cap$66M
Enterprise Value$-43M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-33.2%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-17.5M
Free Cash Flow$-22.0M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-89.9%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.5M
Days to Cover7.6
Change (vs Prior)-19.9%
Need at least 2 settlement dates for chart
Employees
Headcount10
Revenue / Employee$0
Gross Profit / Employee$-73,500
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
38.8%(-18.8% YoY)
31 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
4.4%(-0.0% YoY)
5 filers
Vanguard, iShares, SPDR
Market makers
0.1%(+0.1% YoY)
2 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| BVF INC/IL | $5.6M | $7.28 | +$1.5M | +$5.6M | -0.4% | $3.14B |
| Blue Owl Capital Holdings LP | $4.8M | $7.34 | +$678K | +$4.8M | -2.3% | $372M |
| Cable Car Capital, LP | $3.8M | $6.62 | +$554K | +$3.8M | -23.3% | $238M |
| Omega Fund Management, LLC | $2.3M | $8.15 | +$0 | +$2.3M | -8.9% | $163M |
| ORBIMED ADVISORS LLC | $1.9M | $8.15 | +$0 | +$1.9M | -8.1% | $4.38B |
| RTW INVESTMENTS, LP | $1.7M | $8.15 | +$0 | +$1.7M | -2.2% | $9.26B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $1.6M | $5.00 | +$1.6M | +$1.6M | — | $4.04T |
| BML Capital Management, LLC | $1.0M | $7.79 | +$119K | +$1.0M | -1.6% | $155M |
| BlackRock, Inc.Passive | $646K | $7.40 | −$12K | +$646K | -0.2% | $5.69T |
| CITADEL ADVISORS LLC | $622K | $7.41 | +$189K | +$622K | -0.4% | $138.22B |
| RENAISSANCE TECHNOLOGIES LLC | $408K | $7.11 | +$78K | +$408K | +1.2% | $63.91B |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $333K | $8.15 | +$0 | +$333K | -0.1% | $64.61B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $300K | $7.71 | +$29K | +$300K | +2.3% | $1.61T |
| NEA Management Company, LLC | $250K | $8.15 | +$0 | +$250K | -3.5% | $1.76B |
| HSBC HOLDINGS PLC | $166K | $6.86 | +$3K | +$166K | -0.1% | $167.40B |
| Rangeley Capital, LLC | $163K | $6.64 | +$72K | +$163K | -1.3% | $91.1M |
| Sofinnova Investments, Inc. | $159K | $8.15 | +$0 | +$159K | +2.6% | $1.94B |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $150K | $6.68 | +$18K | +$150K | +1.9% | $106M |
| VANGUARD FIDUCIARY TRUST COPassive | $136K | $5.00 | +$136K | +$136K | — | $395.83B |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $133K | $7.16 | +$40K | +$133K | +0.4% | $23.79B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-5.95%
avg per quarter
Holders (ex-self)
-5.93%
excl. this stock
Buyers (this Q)
-0.64%
12 buyers · $0.00B in
Sellers (this Q)
+0.01%
5 sellers · $0.00B out
alpha coverage: 93% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+9.0%
how holders react when this stock falls
On quiet Qs
-1.3%
−10% to +10% baseline
On rallies (+10%+)
-9.0%
how they react when this stock rises
Holders' portfolio flow this Q
-25.9%
outflows — trims may be forced
Sellers' portfolio flow this Q
+3.6%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.2%
Holder mid (any stock)
-1.3%
Holder rally (any stock)
-9.0%
Biggest decreases this quarter
Monashee Investment Management LLCexited−$632KSquarepoint Ops LLCexited−$333KDRW Securities, LLCexited−$302KT3 Companies, LLCexited−$91KMILLENNIUM MANAGEMENT LLCexited−$79KShay Capital LLC−$20Kα+0.3BANK OF AMERICA CORP /DE/exited−$18KBlackRock, Inc.−$12Kα-0.2NewEdge Advisors, LLCexited−$3KFortitude Family Office, LLCexited−$3K
New buyers this quarter
Top-5 holders · 68.3%
BVF INC/IL--
Blue Owl Capital Holdings LP--
Cable Car Capital, LP--
Omega Fund Management, LLC--
ORBIMED ADVISORS LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Deep Track Capital, LP—BVF INC/IL1.1MBlue Owl Capital Holdings LP959KCable Car Capital, LP755KOmega Fund Management, LLC455KORBIMED ADVISORS LLC379KAtlas Venture Life Science Advisors, LLC—RTW INVESTMENTS, LP334KBML Capital Management, LLC201KCITADEL ADVISORS LLC124K
Analyst Coverage
Analyst Coverage
Analyst Ratings
4
1
Buy: 4Sell: 1Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$10.60M
5 txns · 4 insiders · 1,809,751 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-04-14 | BUY | Bonita David P | director | 721,292 | $0.00 | $721 | $385 |
| 2026-04-14 | BUY | ORBIMED ADVISORS LLC | director | 721,292 | $0.00 | $721 | $385 |
| 2025-12-24 | BUY | SLATTERY JOSEPH P | director | 16,000 | $5.99 | $96K | $96K |
| 2025-07-25 | BUY | Bonita David P | director | 83,611 | $29.90 | $2.50M | $8.61M |
| 2025-07-25 | BUY | Stampacchia Otello | director | 267,556 | $29.90 | $8.00M | $13.60M |
Order Flow (FINRA, ~3w lag)
43.8%retail-4.6pp
2.9%dark+2.7pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
ImageneBio, Inc.: Circular Related-Party Spin-offs and Pre-Merger Debt Forgiveness
Overall Risk
7/10
Fraud
5/10
Dilution
8/10
Insolvency
4/10
Earnings Overstated
3/10
Hidden Liabilities
6/10
Legal
5/10
Audit Warnings
2/10
Hidden Upside
5/10
Contextually Acceptable
6/10